2006 to 2020 Saw Decrease in Death Following First Heart Attack
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 21, 2023 -- Death rates following a first heart attack decreased for those without diabetes or with type 2 diabetes (T2D), but not for those with type 1 diabetes (T1D), according to a study scheduled to be presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.
Linn Glynn, from the Karolinska Institutet in Stockholm, and colleagues compared trends in survival after a first myocardial infarction in people with and without diabetes. The analysis included 2,527 individuals with T1D, 48,321 individuals with T2D, and 243,170 individuals without diabetes with a first myocardial infarction identified through national health care registries (2006 to 2020).
The researchers found that during follow-up (up to 1,095 days), there was a significant decreased annual incidence trend for all-cause death in the control group (−1.9 percent) and individuals with T2D (−1.3 percent), but no such trend was seen in individuals with T1D (0 percent) in an adjusted analysis. There was a decrease in the annual incidence of cardiovascular death observed for the control (−2.0 percent), T2D (−1.6 percent), and T1D (−0.5 percent) groups. Findings were similar for major cardiovascular events in the control (−2.3 percent), T2D (−1.9 percent), and T1D (−0.6 percent) groups.
"During the last 15 years, the trend in death and major cardiovascular events in people without diabetes and with T2D having a first-time myocardial infarction has decreased significantly," the authors write. "In contrast, such a decreased trend was absent in people with T1D. This finding highlights the urgent need for understanding the cardiovascular risk in people with T1D."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.